153 related articles for article (PubMed ID: 30726626)
1. Sacubitril + valsartan (Entresto°) in chronic heart failure.
Prescrire Int; 2017 Feb; 26(179):33-37. PubMed ID: 30726626
[No Abstract] [Full Text] [Related]
2. Sacubitril/Valsartan (Entresto) for Heart Failure.
Cheng J
Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
[No Abstract] [Full Text] [Related]
3. ▼ Sacubitril valsartan for heart failure.
Drug Ther Bull; 2016 Jun; 54(6):66-9. PubMed ID: 27284124
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
5. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
6. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey.
Moulis F; Rousseau V; Chebane L; Gouverneur A; Gaboriau L; Faillie JL; Durrieu G; Montastruc F; Montastruc JL
Eur J Clin Pharmacol; 2018 Jul; 74(7):983-984. PubMed ID: 29656309
[No Abstract] [Full Text] [Related]
7. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
McCormack PL
Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Norberg H; Bergdahl E; Lindmark K
Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
[TBL] [Abstract][Full Text] [Related]
9. Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis.
Okutucu S; Bursa N
Int J Cardiol; 2019 Aug; 288():117. PubMed ID: 31101225
[No Abstract] [Full Text] [Related]
10. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan (Entresto) for heart failure.
Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
[No Abstract] [Full Text] [Related]
12. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.
Jaffuel D; Molinari N; Berdague P; Pathak A; Galinier M; Dupuis M; Ricci JE; Mallet JP; Bourdin A; Roubille F
ESC Heart Fail; 2018 Jun; 5(3):222-230. PubMed ID: 29469206
[TBL] [Abstract][Full Text] [Related]
13. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
[No Abstract] [Full Text] [Related]
14. Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
Fuzaylova I; Lam C; Talreja O; Makaryus AN; Ahern D; Cassagnol M
J Pharm Pract; 2020 Oct; 33(5):696-699. PubMed ID: 30776953
[TBL] [Abstract][Full Text] [Related]
15. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
[TBL] [Abstract][Full Text] [Related]
16. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
Srivastava PK; Fonarow GC
JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
[No Abstract] [Full Text] [Related]
17. What will be the impact of sacubitril/valsartan in clinical practice?
Metra M
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e88-e90. PubMed ID: 29084021
[No Abstract] [Full Text] [Related]
18. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC
Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
[TBL] [Abstract][Full Text] [Related]
19. Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.
Daly A; Coughlan JJ; Mross T; Wafer M; O'Connor A; Liston R
Ir J Med Sci; 2019 Nov; 188(4):1169-1174. PubMed ID: 30796605
[TBL] [Abstract][Full Text] [Related]
20. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
